BMJ Open

Comparative efficacy and safety of oral anticoagulants for the treatment of venous thromboembolism in the patients with different renal functions: a systematic review, pairwise and network meta-analysis

Xiaole Su,[1,2] Bingjuan Yan,[2] Lihua Wang,[2] Hong Cheng,[1] Yipu Chen [1]

To cite: Su X, Yan B, Wang L, *et al*. Comparative efficacy and safety of oral anticoagulants for the treatment of venous thromboembolism in the patients with different renal functions: a systematic review, pairwise and network meta-analysis. *BMJ Open* 2022;**12**:e048619. doi:10.1136/bmjopen-2021-048619

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/bmjopen-2021-048619).

Received 02 January 2021
Accepted 24 January 2022

[1]Department of Nephrology, Beijing Anzhen Hospital, Capital Medical University, Chaoyang District, Beijing, China
[2]Department of Nephrology, Shanxi Medical University Second Hospital, Shanxi Kidney Disease Institute, Taiyuan, Shanxi, China

Correspondence to
Dr Yipu Chen;
chen_yipu@163.com

ABSTRACT

Objectives To compare the efficacy and safety of direct oral anticoagulants (DOACs) in patients with venous thromboembolism (VTE) and different renal functions.

Design Systematic review containing pairwise and Bayesian network meta-analysis of randomised controlled trials (RCTs).

Data sources MEDLINE, EMBASE and Cochrane Library.

Eligibility criteria RCTs reporting the efficacy and safety outcomes of DOACs in different creatinine clearance (CrCl) subgroups.

Data extraction and synthesis Data extraction and quality assessment were undertaken by two independent reviewers. Data were pooled using the DerSimonian-Laird method in pairwise meta-analysis. Network meta-analysis within a Bayesian framework was conducted.

Results Data from 10 RCTs were included. In the treatment of acute VTE, DOACs did not significantly reduce recurrent VTE or VTE-related death (OR, 0.96; 95% CI, 0.82 to 1.11) but significantly reduced bleeding events (0.76, 0.68 to 0.90) compared with warfarin. In the extended treatment of VTE, DOACs produced significant benefits in recurrent VTE or VTE-related death (0.23, 0.16 to 0.29), but significantly increased bleeding events (1.86, 1.04 to 3.33) compared with placebo/aspirin. There were no significant differences in efficacy and safety of DOACs among the three CrCl stratified subgroups in acute and extended treatment of VTE (p for subgroup heterogeneity >0.1). Bayesian network meta-analysis suggested that apixaban 2.5 mg and 5 mg two times per day were associated with a lower risk of bleeding than dabigatran, rivaroxaban, warfarin and aspirin in the subgroup with CrCl >80 mL/min.

Conclusions For the treatment of acute VTE, DOACs are similar to warfarin in reducing recurrent VTE and VTE-related death but are significantly superior to warfarin in reducing the risk of bleeding. For the efficacy and safety of DOACs across different CrCl stratifications (30–50, 50–80 and more than 80 mL/min), no significant difference was found. In light of minimal evidence, apixaban might be associated with a lower risk of bleeding in patients with VTE and CrCl >80 mL/min.

Strengths and limitations of this study

- The systematic review, pairwise and network meta-analysis included 10 high-quality randomised controlled trials comprising 37 298 patients and attempted to assess the efficacy and safety of direct oral anticoagulants (DOACs) in the patients with venous thromboembolism (VTE) and different renal functions.
- Data were classified and pooled based on the creatinine clearance (CrCl) levels in patients receiving acute or extended treatment of VTE.
- Network meta-analysis within a Bayesian framework was conducted to explore the relative efficacy and safety profiles of different DOAC interventions in three CrCl stratifications and to attempt to explain partly the source of heterogeneity in pairwise meta-analysis.
- The Grading of Recommendations Assessment, Development and Evaluation guidelines and the Confidence in Network Meta-analysis internet application were used to determine the strength of evidence in pairwise and network meta-analysis.
- The inadequate sample size and lower event rate in patients with mild to moderate renal impairment (CrCl 30–50 and 50–80 mL/min, respectively) might affect the results of our research.

PROSPERO registration number CRD42018090896.

INTRODUCTION

With a prevalence reaching 10.5%–13.1%, the incidence of chronic kidney disease (CKD) is increasing.[1] Venous thromboembolism (VTE), with an estimated incidence of 0.7–1.4 per 1000 person-years,[2] which encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common and potentially fatal disease. There is an increased risk of VTE in patients with nephrotic syndrome,[3]

those receiving maintenance dialysis[4] and kidney transplant recipients.[5 6] In a large prospective cohort study, a glomerular filtration rate (GFR) of less than 45 mL/min was associated with a 2.13-fold increased risk of VTE compared with a GFR of more than 90 mL/min.[7]

The introduction of direct oral anticoagulants (DOACs), including direct inhibitors of thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban, edoxaban), has changed the landscape of VTE treatment. Based on several landmark randomised controlled trials (RCTs),[8–11] the 2014 European Society of Cardiology Guidelines on acute PE suggested that rivaroxaban, apixaban or dabigatran should be considered as an alternative to vitamin K antagonist (VKA) during extended oral anticoagulation (OAC) therapy.[12] The 2016 American College of Chest Physicians Treatment Guideline for VTE suggested DOACs (dabigatran, rivaroxaban, apixaban or edoxaban) over VKA therapy in patients with VTE and no cancer.[13]

The different pharmacokinetic characteristics of the four DOACs, including the half-life, the elimination process, the administration and the fluctuation of plasma concentrations, might result in different efficacy and safety profiles, especially for the patients with VTE and impaired renal function. In patients with different renal functions, there are currently no RCTs to directly compare the efficacy and safety of the different DOAC regimens, leading to uncertainty in the selection of clinical treatment regimens. Therefore, whether there is a relatively optimal DOAC treatment regimen in patients with VTE and impaired renal function is a prominent issue.

In this systematic review, our aim was to synthesise all the available data from RCTs and then evaluate the therapeutic benefits and adverse effects of DOACs in patients with VTE stratified by different creatinine clearance (CrCl) levels. Furthermore, we attempted to explore whether there is heterogeneity among DOACs by means of a network meta-analysis within a Bayesian framework.

METHODS

Data sources and searches

This systematic review is performed according to a prespecified protocol[14] registered at the International Prospective Register of Systematic Reviews (CRD42018090896), and the report is in line with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.[15] We searched MEDLINE via Ovid, EMBASE via Ovid and the Cochrane Library database (before July 2019) for RCTs (see online supplemental item 1 for full search terms). The ClinicalTrials.gov website was also searched for RCTs that were registered as completed but not yet published. If a trial was published in more than one publication, we used the most detailed publication.

Study selection and outcome definition

We included RCTs of adult patients with VTE (DVT, PE or both) treated with DOACs (dabigatran, rivaroxaban, apixaban or edoxaban), which reported outcomes in different renal function subgroups. The acute and extended treatment of VTE were both included in our analysis. The control groups included anticoagulant-control group (using warfarin as a control, including warfarin alone and enoxaparin followed by warfarin) and non-anticoagulant-control group (using aspirin or placebo as a control). All trials must have an assessment of the efficacy and safety outcomes of DOACs. The efficacy outcome included recurrent VTE and VTE-related death. The safety outcome included major bleeding and clinically relevant non-major bleeding, which were defined individually by each trial. The definitions of efficacy outcome and safety outcome in every trial are presented in online supplemental table 1. The CrCl was calculated by Cockcroft-Gault formula in all trials, which were expressed as mL/min.

Data extraction and quality assessment

Published reports were obtained for each eligible trial, and relevant information was extracted into a spreadsheet by investigator pairs on the basis of methodological and clinical experience. We used the new Cochrane risk of bias tool for RCTs to assess methodological quality of each study.[16] The literature search, study selection, data extraction and quality assessment were undertaken independently by two authors (XS and BY) using a standardised approach according to the predefined protocol. Disagreement was resolved by consensus or by a third-party arbitrator.

Data synthesis and analysis

Data were classified based on the CrCl levels in patients receiving acute or extended treatment of VTE. The random-effects model was applied to generate the summary values according to DerSimonian-Laird method[17] and the CIs according to Knapp-Hartung modified method.[18] All of the above operations were run using the software Stata V.12.0 (StataCorp). ORs and 95% CIs of individual study were calculated from event numbers and the total population at risk extracted from each trial. The percentage of variability across studies attributable to heterogeneity beyond chance was estimated using the I^2 statistic. X^2 test was used to assess the between-subgroup heterogeneity.

Four DOACs were pooled as a whole and compared with controls in pairwise meta-analysis. Network meta-analysis within a Bayesian framework was conducted to explore the relative efficacy and safety profiles of different OAC interventions and to attempt to explain partly the source of heterogeneity in pairwise meta-analysis. Relative effects of different OACs were measured by OR and its 95% credible intervals. The above operations are run by WinBUGS V.1.4.3 and the R2WinBUGS package of the R software V.3.1.1. We used non-informative priors with vague normal (mean, 0; variance, 100 000) and uniform (0–5) prior distributions for parameters such as the means and SDs, respectively.[19] For each analysis, we generated 200 000 simulations for each of the two sets of

different initial values and discarded the first 80 000 simulations as the burn-in period. Convergence was reached when Rhat, the potential scale reduction factor, was close to 1 for each of the parameters using the Brooks-Gelman-Rubin statistic.[20] We selected the model with a lower value of deviance information criterion (DIC), which suggests a more parsimonious model.[21] We used the surface under the cumulative ranking curve (SUCRA) probabilities to rank the treatments.

We summarised strength of evidence (SOE) for each outcome individually according to the Grading of Recommendations Assessment, Development and Evaluation guidelines.[22] The Confidence in Network Meta-analysis internet application was used to determine the confidence in network estimates.[23] Confidence was initially considered to be high and was maintained or downgraded to moderate, low or very low according to the assessment of the quality of the evidence.[24]

Patient and public involvement

Patients or the public were not involved in the design, conduct, reporting or dissemination of our research.

RESULTS

Study search and study characteristics

A total of 6089 records were identified during our search, and 601 potentially eligible full-text articles were retrieved (figure 1). Overall, 10 RCTs reported in eight articles,[8–10 25–29] comprising 37 298 eligible patients, were eventually included in our analysis (see online supplemental table 2 for the details of included studies). All 10 trials were multicentre studies with an average study sample size of 3730 participants. The DOACs in these trials included dabigatran, rivaroxaban, apixaban and edoxaban. In all five trials for the treatment of acute VTE, DOACs were compared with warfarin alone[26] or enoxaparin followed by warfarin.[8–10 29] For the extended treatment of VTE, DOACs were compared with placebo in three trials,[25–27] with aspirin in one trial,[28] and with warfarin in one trial.[27] To date, no RCT has conducted head-to-head comparisons between different DOACs. Eight RCTs excluded patients with a CrCl of <30 mL/min, whereas the cut-off was slightly lower (<25 mL/min) in the two RCTs that included apixaban treatment.[8 25] Nine RCTs involved three CrCl stratifications (25/30–50 mL/min, 50–80 mL/min and >80 mL/min), and one RCT involved two CrCl stratifications (30–50 and >50 mL/min).[10] The detailed results of the risk of bias assessment in the included trials are summarised in online supplemental table 3. The overall methodological quality of the 10 RCTs was moderate to high.



Figure 1 Summary of trial identification and selection. CKD, chronic kidney disease; CrCl, creatinine clearance; RCTs, randomised controlled trials; VTE, venous thromboembolism.

Pairwise meta-analysis

The efficacy outcome

No statistically significant difference was observed between DOACs as a whole and warfarin for recurrent VTE or VTE-related death in patients with acute VTE (OR, 0.96; 95% CI, 0.82 to 1.11; 5 RCTs enrolled 26 269 patients with 703 events; high SOE) without significant heterogeneity (I^2=0%). In patients with extended treatment for VTE, the use of DOACs produced significant benefits for recurrent VTE or VTE–related death compared with placebo/aspirin (OR, 0.23; 95% CI, 0.16 to 0.29; 4 RCTs enrolled 8205 patients with 260 events; moderate SOE) without significant heterogeneity (I^2=0%).

The effects of DOACs on recurrent VTE or VTE-related death in patients with acute and extended treatment of VTE were not significantly different among the three subgroups of CrCl stratifications (p values for subgroup heterogeneity were 0.45 and 0.78, respectively). The RE-MEDY trial comparing dabigatran with warfarin is the only trial designed to specifically evaluate the efficacy of DOAC against VKA during the extended treatment of VTE, in which no significant difference was found for recurrent VTE or VTE-related death among the subgroups of different CrCl stratifications.[27]



Figure 2 Summary of the efficacy outcome of DOACs therapy according to different CrCl subgroups. *Zero event in at least one treatment arm. Api, apixaban; CrCl, creatinine clearance; Dabi, dabigatran; DOACs, direct oral anticoagulants; Edo, edoxaban; Riva, rivaroxaban; VTE, venous thromboembolism.

The details of the efficacy outcomes are presented in figure 2.

The safety outcome

In patients with acute VTE, DOACs therapy significantly reduced the risk of bleeding events compared with warfarin (OR, 0.76; 95% CI, 0.68 to 0.90; 26 182 patients with 2473 events; moderate SOE). Conversely, in patients with extended treatment of VTE, the use of DOACs significantly increased the risk of bleeding events compared with aspirin/placebo (OR, 1.86; 95% CI, 1.04 to 3.33; 6859 patients with 209 events; low SOE). However, significant heterogeneity was found in the safety outcome for both acute and extended VTE treatment (I^2=47.6% and 55.1%; p for heterogeneity=0.02 and 0.02, respectively). The subgroup analysis suggested that the main contribution of heterogeneity across studies was from the subgroup of CrCl >80 mL/min (I^2=85% in acute treatment and 78.5% in extended treatment).

In patients with acute and extended treatment of VTE, no significant difference in bleeding events was found among the three subgroups of CrCl stratifications (p for subgroup heterogeneity=0.63 and 0.21, respectively).

The details of the safety outcomes are presented in figure 3. The SOE grades (low, moderate or high) and the details of all comparisons and outcomes are summarised and provided in online supplemental table 4.

Bayesian network meta-analysis

Network meta-analysis within a Bayesian framework was conducted to explore the relative efficacy and safety of different treatment regimens and to attempt to explain the source of heterogeneity in pairwise meta-analysis. There were seven, nine and eight treatment regimens in patients with VTE with CrCl of 30–50, 50–80 and more than 80 mL/min, respectively. The networks of eligible comparisons are shown in online supplemental figure 1. The DIC values from the fixed consistency model were



Figure 3 Summary of the safety outcome of DOACs therapy according to different CrCl subgroups. Api, apixaban; CrCl, creatinine clearance; Dabi, dabigatran; DOACs, direct oral anticoagulants; Edo, edoxaban; Riva, rivaroxaban; VTE, venous thromboembolism.

the lowest, which indicates that it was the preferred model (online supplemental table 5). The primary outcomes of the Bayesian network meta-analysis from the three CrCl subgroups, including recurrent VTE or VTE-related death and bleeding events, are summarised in figure 4.

In patients with VTE with CrCl of 30–50 mL/min and 50–80 mL/min, there was no significant difference in recurrent VTE or VTE-related death and bleeding events between any two OACs (figure 4A,B).

In patients with VTE with CrCl greater than 80 mL/min, the significant differences between treatment regimens were mainly from the safety outcomes (figure 4C, the upper triangle with yellow shading). Apixaban 2.5 mg and 5 mg two times per day were associated with reduced bleeding risks compared with the other treatment regimens, including dabigatran 150 mg two times per day, rivaroxaban 10 mg and 20 mg once daily, warfarin and aspirin. No significant difference was found between apixaban 2.5 mg and 5 mg two times per day. Dabigatran 150 mg two times per day was superior to rivaroxaban 20 mg once daily and warfarin in reducing bleeding events: the ORs (95% CIs) were 0.61 (0.47 to 0.81) and 0.62 (0.51 to 0.74), respectively. These results might partly explain the source of heterogeneity in pairwise meta-analysis, especially when bleeding events were analysed in the subgroup of CrCl greater than 80 mL/min.

Because almost all the 95% CIs of the SUCRAs overlapped widely in all three CrCl subgroups, the implications of SUCRA might be limited (online supplemental table 6). Only one to two closed loops were formed, and no significant inconsistency was identified (online supplemental figure 2). The confidence ratings for the effect estimates of outcomes are presented in online supplemental table 7, most of which were low and very low.

DISCUSSION

How to carry out reasonable anticoagulation therapy for VTE in the patients with renal insufficiency is a very important clinical issue. For acute and extended treatments in patients with VTE with different kidney functions, the subgroup analyses of several large RCTs have

A: CrCl 30-50 mL/min								
Api 5 mg	1.20 (0.43,3.45)	1.04 (0.31,3.45)	1.09 (0.33,3.57)	0.66 (0.17,2.56)	1.52 (0.56,4.55)	0.48 (0.11,1.75)	—	—
0.97 (0.21,2.99)	Riva 20 mg	0.85 (0.39,1.75)	0.88 (0.45,1.75)	0.54 (0.09,2.94)	1.27 (0.81,1.99)	0.38 (0.07,1.85)	—	—
5.66 (0.38,28.83)	6.79 (0.56,26.94)	Dabi 150 mg	1.03 (0.47,2.27)	0.65 (0.09,3.85)	1.47 (0.83,2.86)	0.46 (0.08,2.63)	—	—
2.04 (0.39,6.39)	2.55 (0.63,7.65)	0.92 (0.06,3.73)	Edo 30 mg	0.61 (0.11,3.13)	1.41 (0.83,2.51)	0.43 (0.08,2.22)	—	—
0.85 (0.03,4.32)	1.23 (0.04,6.51)	0.49 (0.01,2.61)	0.75 (0.02,3.33)	Api 2.5 mg	2.27 (0.47,14.29)	0.71 (0.15,3.33)	—	—
0.85 (0.25,2.20)	1.06 (0.43,2.35)	0.39 (0.03,1.41)	0.52 (0.18,1.05)	5.46 (0.16,29.1)	Warfarin	0.31 (0.06,1.41)	—	—
0.19(0.02,0.72)	**0.24(0.02,0.85)**	**0.09(0.01,0.42)**	**0.13(0.01,0.54)**	0.58 (0.04,2.09)	**0.26(0.02,0.88)**	Placebo	—	—
B: CrCl 50-80 mL/min								
Api 5 mg	1.71 (0.73,6.17)	1.49 (0.62,5.56)	1.67 (0.71,5.81)	0.98 (0.28,6.71)	0.81 (0.32,2.48)	1.08 (0.34,6.45)	2.04 (0.88,7.19)	**0.24(0.08,0.91)**
1.87 (0.75,3.89)	Riva 20 mg	0.86 (0.59,1.28)	0.96 (0.72,1.32)	0.59 (0.24,2.14)	0.35 (0.11,1.93)	0.64 (0.26,2.28)	1.17 (0.92,1.55)	**0.11(0.03,0.55)**
1.17 (0.39,2.82)	0.68 (0.23,1.49)	Dabi 150 mg	1.09 (0.77,1.56)	0.66 (0.24,2.67)	0.39 (0.11,2.09)	0.71 (0.26,2.61)	1.34(1.00,1.92)	**0.13(0.04,0.69)**
1.61 (0.71,3.32)	0.92 (0.47,1.64)	1.56 (0.65,3.18)	Edo 60 mg	0.61 (0.23,2.39)	0.36 (0.11,1.98)	0.65 (0.25,2.34)	1.21(1.00,1.53)	**0.12(0.04,0.58)**
1.36 (0.09,6.02)	0.72 (0.05,2.74)	1.32 (0.08,5.89)	0.86 (0.06,3.71)	Riva 10 mg	0.42 (0.11,4.59)	0.91 (0.33,3.17)	1.43 (0.54,5.24)	0.13 (0.03,1.25)
1.03 (0.24,2.89)	0.64 (0.13,2.02)	0.40 (0.03,1.57)	0.72 (0.16,2.28)	2.47 (0.11,14.52)	Api 2.5 mg	1.03 (0.25,9.43)	1.94 (0.63,11.36)	0.25 (0.07,1.16)
0.41 (0.04,1.59)	**0.22(0.02,0.74)**	1.03 (0.22,3.47)	**0.26(0.03,0.96)**	0.41 (0.09,1.09)	0.55 (0.03,2.52)	Aspirin	1.36 (0.54,4.93)	0.13 (0.03,1.18)
1.49 (0.69,2.93)	0.85 (0.48,1.38)	1.44 (0.63,2.88)	0.94 (0.73,1.22)	3.32 (0.25,15.36)	2.06 (0.43,5.72)	8.87 (0.99,37.71)	Warfarin	**0.11(0.03,0.49)**
0.18(0.06,0.38)	**0.11(0.03,0.26)**	**0.18(0.05,0.41)**	**0.12(0.04,0.29)**	0.43 (0.02,2.42)	**0.22(0.06,0.48)**	1.15 (0.11,5.36)	**0.13(0.04,0.29)**	Placebo
C: CrCl >80 mL/min								
Api 5 mg	**5.26(2.78,14.29)**	**3.33(1.64,8.33)**	**3.98(1.82,14.29)**	0.65 (0.35,1.28)	**2.33(1.01,8.33)**	**5.26(2.71,14.29)**	0.68 (0.39,1.28)	—
1.12 (0.32,4.66)	Riva 20 mg	**0.61(0.47,0.81)**	0.76 (0.45,1.39)	**0.11(0.04,0.31)**	0.44 (0.20,1.01)	1.00 (0.83,1.20)	**0.11(0.05,0.27)**	—
0.99 (0.35,4.49)	0.90 (0.29,3.21)	Dabi 150 mg	1.20 (0.69,2.44)	**0.17(0.07,0.51)**	0.71 (0.36,1.59)	**1.61(1.35,1.96)**	**0.18(0.09,0.46)**	—
1.92 (0.29,13.21)	1.68 (0.40,7.43)	1.91 (0.25,11.18)	Riva 10 mg	**0.13(0.05,0.43)**	0.55 (0.29,1.23)	1.22 (0.71,2.33)	**0.13(0.05,0.41)**	—
0.98 (0.27,3.93)	0.88 (0.18,5.14)	0.97 (0.17,4.52)	0.52 (0.06,4.07)	Api 2.5 mg	**3.33(1.33,14.29)**	**7.69(3.33,24.99)**	0.96 (0.52,2.08)	—
0.44 (0.07,2.35)	0.41 (0.09,1.38)	0.44 (0.05,1.98)	0.38(0.05,1.79)	0.44 (0.05,3.08)	Aspirin	**2.04(1.05,4.35)**	**0.22(0.09,0.77)**	—
1.08 (0.39,3.48)	0.96 (0.41,2.36)	1.07 (0.41,2.34)	0.57 (0.12,3.14)	1.09 (0.21,5.03)	2.42 (0.61,14.97)	Warfarin	**0.11(0.05,0.28)**	—
0.13(0.04,0.41)	**0.11(0.03,0.35)**	**0.13(0.03,0.36)**	**0.07(0.01,0.36)**	**0.13(0.03,0.48)**	0.29 (0.05,1.64)	**0.12(0.04,0.34)**	Placebo	—

Figure 4 Summary of the primary results of Bayesian network meta-analysis from the three CrCl subgroups. (A) CrCl 30–50 mL/min; (B) CrCl 50–80 mL/min; (C) CrCl more than 80 mL/min. Note: column-to-row ORs and 95% CIs for incidence of VTE or VTE-related death (on the lower triangle, light blue shading) and bleeding events (on the upper triangle, yellow shading) were shown. An OR >1 favours the row-defining treatment and means that the treatment in the row is associated with a lower risk of VTE or VTE-related death and bleeding events than the treatment in the column. To obtain ORs for comparisons in the opposite direction, reciprocals should be taken. Significant results are in bold. Api and dabi were administered two times per day, while the other treatments were administered once daily. Api, apixaban; CrCl, creatinine clearance; Dabi, dabigatran; Edo, edoxaban; Riva, rivaroxaban; VTE, venous thromboembolism.

been performed to explore the effectiveness and safety of DOACs therapy. Our study systematically reviewed these research results, which consisted with CrCl stratifications. There were two key findings. First, the efficacy and safety of DOACs had no statistically significant change across different CrCl stratifications (30–50, 50–80 and more than 80 mL/min). Specifically, in patients with acute VTE, DOACs showed similar efficacy to warfarin for the prevention of recurrent VTE or VTE-related death with fewer bleeding events, while in patients with extended treatment of VTE, DOACs significantly reduced the risk of recurrent VTE or VTE-related death, but a significant increase in bleeding complications was found compared with aspirin/placebo. Second, regardless of acute or extended treatment of VTE, significant heterogeneity for bleeding events was found, especially in patients with a CrCl of more than 80 mL/min. The results of the Bayesian network meta-analysis further demonstrated the differences between treatment interventions in patients with a CrCl of more than 80 mL/min: apixaban 2.5 mg or 5 mg two times per day was superior to dabigatran 150 mg two times per day, rivaroxaban 10 mg or 20 mg once daily, aspirin and warfarin, and dabigatran 150 mg two times per day was superior to rivaroxaban 20 mg once daily and warfarin in reducing the risk of bleeding events.

Our systematic review and meta-analysis included only patients with VTE who were treated with OACs, homogenising the research subjects. Furthermore, we attempted to assess the efficacy and safety of DOACs in patients with different renal functions, especially CKD. Subgroup analysis of CrCl stratification was performed for the first time to explore the influence of the severity of renal insufficiency on the actions of OACs. The source of heterogeneity in the outcome of bleeding events in the pairwise meta-analysis is partly explained in Bayesian network meta-analyses. These findings suggest that in terms of safety, there may be some differences between DOACs. However, there are some limitations that may be

considered in our systemic review. First, the inadequate sample size and lower event rate in patients with mild to moderate renal impairment (CrCl 30–50 and 50–80 mL/min, respectively) might affect the results of our research. Second, our study only included RCT data, which may affect the universality of the results because it is generally believed that the risk of bleeding events in clinical trials is often lower than that in clinical practice, especially in patients with severe renal insufficiency. Third, networks are very sparse, so the majority of SOE grades in network meta-analysis were low or very low. Therefore, the findings of our network meta-analysis study should be viewed as hypothesis generating and need to be confirmed in further studies.

In 2019, Ha *et al*[30] published a systematic review and meta-analysis that compared the benefits and harms of various oral and injection anticoagulants in the treatment of patients with CKD with renal insufficiency (CrCl of 20–60 mL/min, estimated GFR 15–60 mL/min/1.73 m^2 or serum creatinine ≥1.5 mg/dL). In Ha *et al*'s study, the indications for anticoagulation treatment included not only VTE but also other disorders, such as atrial fibrillation, cardiovascular diseases other than atrial fibrillation and thromboprophylaxis in the perioperative period. The results showed that DOACs were similar to VKAs in reducing recurrent VTE or VTE-related death in the treatment of acute VTE. In terms of reducing the risk of major bleeding, an analysis combining all indications (not just VTE) showed that DOACs were superior to VKAs, but the difference had not yet reached statistical significance (Risk ratio [RR], 0.75; CI, 0.56 to 1.01). Ha *et al*'s study is a meaningful study, but they did not stratify the patient's renal function, nor did they explore the impact of the severity of renal insufficiency on the efficacy and safety of OACs. Our results further confirm and reinforce Ha *et al*'s findings. In the subgroup analyses of CrCl stratification, we did not find that there were significant differences in the efficacy and safety of DOACs among the three groups (CrCl of 30–50, 50–80 and >80 mL/min, respectively). However, it is still impossible to deny that the severity of renal insufficiency can affect the actions of OACs due to inadequate sample size and a lower event rate. The pairwise meta-analysis by Alhousani *et al*[31] included 10 RCTs and suggested that DOACs, VKA and low-molecular-weight heparin (LMWH) showed no significant difference in preventing recurrent VTEs among patients with CKD, but DOACs had a significantly lower risk of bleeding events irrespective of the level of renal impairment compared with VKAs. The conclusions were essentially consistent with the results of acute VTE treatment in our pairwise meta-analysis. Our analysis divided subjects into acute and extended treatment groups, which is consistent with the original study design and may be more suitable for clinical practice.

Prior to our network meta-analysis, some studies also observed the differences between DOACs. A network meta-analysis published in 2014 showed that rivaroxaban and apixaban had the lowest risk of bleeding compared with other therapeutic regimens, including LMWH with dabigatran and LMWH with edoxaban, in the treatment of acute VTE.[32] Another Bayesian network meta-analysis published in 2015 showed that in the treatment of acute VTE, apixaban was superior to dabigatran, rivaroxaban and edoxaban in the reduction of major bleeding or clinically relevant non-major bleeding.[33] More recently, a retrospective population-based cohort study involving 15 254 patients with acute VTE showed that the use of apixaban was associated with a decreased risk of major bleeding compared with rivaroxaban.[34] The study by Wang *et al*[35] consisted of both direct and indirect analyses and only included four RCTs with 6003 patients in the analysis of patients with VTE. The results showed that rivaroxaban was safer than warfarin in patients with VTE with CrCl 30–79 mL/min, while apixaban's superiority regarding bleeding events was only presented in patients with VTE with CrCl 50–79 mL/min. All the data, including our finding, suggest that differences between DOACs are objective and that apixaban may have advantages in reducing the risk of bleeding compared with other DOACs. In our network meta-analysis, 10 RCTs with 37 298 patients were included and the results appear to be more credible due to the increased study number and sample size.

When DOACs are used in patients with renal insufficiency, due to the difference in pharmacokinetic properties, especially the difference in renal clearance ratio,[36 37] the difference in safety between them may become more obvious. In this case, DOACs with high renal clearance are more likely to accumulate in the body and cause bleeding than those with low renal clearance. However, our research results are contrary to this; that is, differences in DOACs were observed in the subgroup with normal renal function, but not in the subgroup with mild and moderate renal impairment. One possible explanation is that this contradiction is related to the huge differences in sample size and number of events among the three subgroups (the subgroup with CrCl 30–50 mL/min: 2127 patients with 234 bleeding events; 50–80 mL/min: 13 496 patients with 1219 bleeding events; more than 80 mL/min: 33 041 patients with 2682 bleeding events), which led to a decline in statistical power in the first two subgroups, so that the differences between DOACs could not be detected sensitively. Therefore, it is impossible to conclude from this result that there is no difference in DOACs between these two subgroups with impaired renal function. In the future, it will be necessary to expand the sample size and conduct head-to-head RCTs between DOACs for further testing.

Pharmacokinetic studies suggested that the peak-to-trough ratio of rivaroxaban 10–20 mg once daily was approximately 10.4–13.8,[38] and the ratio of edoxaban (at a dose of 90 mg once daily) was 25.8,[39] whereas the average ratios were 3 for apixaban 5 mg two times per day[40] and 1.88 for dabigatran 150 mg two times per day.[41] Peak-to-trough ratios were similarly lower for the two times per day than the once daily dosing regimens, providing less

fluctuation in drug exposure over the dosing interval. A separate analysis comparing DOACs dosed two times per day (dabigatran and apixaban) with those dosed once daily (rivaroxaban and edoxaban) in the atrial fibrillation population found a more favourable safety profile with DOACs dosed two times per day and speculated that the decreased peak-to-trough ratios afforded by two times per day DOACs probably played an important role.[42] Our results of the network meta-analysis seem to confirm the results of this analysis.

Thus, the current study supports the use of DOACs for preventing recurrent VTE or VTE-related death with fewer bleeding events than warfarin in patients with acute VTE and CrCl greater than 30 mL/min in clinical practice. For extended treatment of VTE in patients with different kidney functions, DOACs significantly reduced the risk of recurrent VTE or VTE-related death, while they should be prescribed with caution because of the increased bleeding risk compared with placebo/aspirin. Our study does not permit a definitive conclusion about the preferred DOAC based on low-quality evidence, although we found a trend of apixaban being associated with a reduced risk of bleeding events for patients with VTE with a CrCl of more than 80 mL/min. Detailed characterisation of individual patient risk profiles, careful selection of patients for OAC therapy and intensive monitoring and treatment of patients with atrial fibrillation and CKD may improve outcomes in this high-risk population.

To further verify our results, head-to-head comparative studies with high quality between different DOACs are needed. Currently, a study named 'the Comparisons of Bleeding Risk Between Rivaroxaban and Apixaban' for the treatment of acute VTE is underway (ClinicalTrials.gov identifier: NCT03266783) and has been widely noticed.[43] Moreover, patients with severe renal insufficiency are at a particularly high risk of both thromboembolism and bleeding, but no high-quality evidence-based recommendations exist to guide the management of these patients. Further research in this area is needed.

In summary, the results of meta-analyses suggest that DOACs as a whole are similar to warfarin in reducing recurrent VTE and VTE-related death but are significantly superior to warfarin in reducing the risk of bleeding in the treatment of acute VTE. Furthermore, the possible effects of renal insufficiency on the efficacy and safety of DOACs have not been confirmed, which needs further study after expanding the sample size in the future. The results of network meta-analyses suggest that DOACs are heterogeneous in terms of safety, and the preferred agents of different DOACs remain inconclusive although our study showed that apixaban may be superior to other DOACs in reducing the risk of bleeding. In clinical practice, the use of OACs, including DOACs, to treat VTE in patients with renal insufficiency still needs to be very carefully and closely monitored.

Acknowledgements The authors would like to thank the authors of the studies they used to conduct this study.

Contributors Research idea and study design—XS and YC. Data acquisition—XS and BY. Data analysis/interpretation—XS, LW and YC. Statistical analysis—XS. Manuscript drafting—XS. Revising manuscript—YC. Supervision or mentorship—YC and HC. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. YC and XS take responsibility that this study has been reported honestly, accurately, and transparently; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained. YC is responsible for the overall content as guarantor. The guarantor accepts full responsibility for the finished work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

Funding This work was supported by grants from the National Science Foundation of China (82000655) and Capital Foundation of Medical Developments (CFMD 2018–2–1051).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval This study does not involve human participants.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplemental information.

ORCID iD

Yipu Chen http://orcid.org/0000-0002-5079-4334

REFERENCES

1 Lv J-C, Zhang L-X. Prevalence and disease burden of chronic kidney disease. *Adv Exp Med Biol* 2019;1165:3–15.
2 Tritschler T, Kraaijpoel N, Le Gal G, *et al*. Venous thromboembolism: advances in diagnosis and treatment. *JAMA* 2018;320:1583–94.
3 Kayali F, Najjar R, Aswad F, *et al*. Venous thromboembolism in patients hospitalized with nephrotic syndrome. *Am J Med* 2008;121:226–30.
4 Tveit DP, Hypolite IO, Hshieh P, *et al*. Chronic dialysis patients have high risk for pulmonary embolism. *Am J Kidney Dis* 2002;39:1011–7.
5 Abbott KC, Cruess DF, Agodoa LYC, *et al*. Early renal insufficiency and late venous thromboembolism after renal transplantation in the United States. *Am J Kidney Dis* 2004;43:120–30.
6 Poli D, Zanazzi M, Antonucci E, *et al*. Renal transplant recipients are at high risk for both symptomatic and asymptomatic deep vein thrombosis. *J Thromb Haemost* 2006;4:988–92.
7 Cheung KL, Zakai NA, Folsom AR, *et al*. Measures of kidney disease and the risk of venous thromboembolism in the REGARDS (reasons for geographic and racial differences in stroke) study. *Am J Kidney Dis* 2017;70:182–90.
8 Agnelli G, Buller HR, Cohen A, *et al*. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med* 2013;369:799–808.
9 EINSTEIN–PE Investigators, Büller HR, Prins MH, *et al*. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. *N Engl J Med* 2012;366:1287–97.
10 Hokusai-VTE Investigators, Büller HR, Décousus H, *et al*. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. *N Engl J Med* 2013;369:1406–15.

11 Schulman S, Kearon C, Kakkar AK, *et al*. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *N Engl J Med* 2009;361:2342–52.
12 Konstantinides SV, Torbicki A, Agnelli G, *et al*. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. *Eur Heart J* 2014;35:997–1053.
13 Kearon C, Akl EA, Ornelas J, *et al*. Antithrombotic therapy for VTe disease: chest guideline and expert panel report. *Chest* 2016;149:315–52.
14 Su X, Chen Y, Yan B. Comparative effectiveness and safety of different anticoagulant agents in patients with thromboembolic risk and chronic kidney disease: a systematic review and Bayesian network meta-analysis. prospero 2018 CRD42018090896. Available: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018090896
15 Moher D, Liberati A, Tetzlaff J, *et al*. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
16 Sterne JAC, Savović J, Page MJ, *et al*. Rob 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;366:l4898.
17 DerSimonian R, Laird N. Meta-Analysis in clinical trials. *Control Clin Trials* 1986;7:177–88.
18 Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. *Stat Med* 2003;22:2693–710.
19 Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. *Stat Med* 2004;23:3105–24.
20 Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. *J Comput Graph Stat* 1998:434–55.
21 Leucht S, Cipriani A, Spineli L, *et al*. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet* 2013;382:951–62.
22 Guyatt GH, Oxman AD, Kunz R, *et al*. What is "quality of evidence" and why is it important to clinicians? *BMJ* 2008;336:995–8.
23 University of Bern. *Confidence in Network Meta-analysis [computer program*. Bern, Switzerland, 2017. cinema.ispm.ch
24 Nikolakopoulou A, Higgins JPT, Papakonstantinou T, *et al*. Cinema: an approach for assessing confidence in the results of a network meta-analysis. *PLoS Med* 2020;17:e1003082.
25 Agnelli G, Buller HR, Cohen A, *et al*. Apixaban for extended treatment of venous thromboembolism. *N Engl J Med* 2013;368:699–708.
26 EINSTEIN Investigators, Bauersachs R, Berkowitz SD, *et al*. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med* 2010;363:2499–510.
27 Schulman S, Kearon C, Kakkar AK, *et al*. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. *N Engl J Med* 2013;368:709–18.
28 Weitz JI, Lensing AWA, Prins MH, *et al*. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. *N Engl J Med* 2017;376:1211–22.
29 Goldhaber SZ, Schulman S, Eriksson H, *et al*. Dabigatran versus warfarin for acute venous thromboembolism in elderly or impaired renal function patients: pooled analysis of RE-COVER and RE-COVER II. *Thromb Haemost* 2017;117:2045–52.
30 Ha JT, Neuen BL, Cheng LP, *et al*. Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis. *Ann Intern Med* 2019;171:181–9.
31 Alhousani M, Malik SU, Abu-Hashyeh A, *et al*. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: a systematic review and meta-analysis. *Thromb Res* 2021;198:103–14.
32 Castellucci LA, Cameron C, Le Gal G, *et al*. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. *JAMA* 2014;312:1122–35.
33 Cohen AT, Hamilton M, Mitchell SA, *et al*. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. *PLoS One* 2015;10:e0144856.
34 Dawwas GK, Brown J, Dietrich E, *et al*. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. *Lancet Haematol* 2019;6:e20–8.
35 Wang Z, Xiang Q, Hu K, *et al*. Comparison of the safety and efficacy of direct oral anticoagulants and warfarin in atrial fibrillation or venous thromboembolism in patients with renal impairment: systematic review, meta-analysis and network meta-analysis. *Am J Cardiovasc Drugs* 2021;21:643–57.
36 Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. *Nat Rev Nephrol* 2018;14:337–51.
37 Weber J, Olyaei A, Shatzel J. The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: a review of the literature. *Eur J Haematol* 2019;102:312–8.
38 Mueck W, Stampfuss J, Kubitza D, *et al*. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. *Clin Pharmacokinet* 2014;53:1–16.
39 Ogata K, Mendell-Harary J, Tachibana M, *et al*. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. *J Clin Pharmacol* 2010;50:743–53.
40 Frost C, Nepal S, Wang J, *et al*. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. *Br J Clin Pharmacol* 2013;76:776–86.
41 Clemens A, Haertter S, Friedman J, *et al*. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. *Curr Med Res Opin* 2012;28:195–201.
42 Clemens A, Noack H, Brueckmann M, *et al*. Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria. *PLoS One* 2014;9:e99276.
43 ClinicalTrials.gov. Us national library of medicine. Available: https://www.clinicaltrials.gov/ct2/show/NCT03266783

ONLINE-ONLY SUPPLEMENTS



Supplemental Figure 1. Network of treatment comparisons for Bayesian network meta-analysis.

A. The network of the primary efficacy outcome in VTE patients with CrCl 30-50 mL/min; B. The network of the primary safety outcome in VTE patients with CrCl 30-50 mL/min; C. The network of the primary efficacy outcome in VTE patients with CrCl 50-80 mL/min; D. The network of the safety outcome in VTE patients with CrCl 50-80 mL/min; E. The network of the primary efficacy outcome in VTE patients with CrCl more than 80 mL/min; F. The network of the safety outcome in VTE patients with CrCl more than 80 mL/min. Directly comparable treatments are linked with a line, the width of which is proportional to the number of trials comparing the connected treatments. Apixaban and dabigatran were administered twice daily, while the other treatments were administered once daily. CrCl = creatinine clearance; VTE = venous thromboembolism.

Supplemental Figure 2. Assessment of inconsistency



We estimated inconsistency as the difference between direct and indirect estimates (called inconsistency factor, IF) and the corresponding 95% confidence intervals (CI) for IF in each closed loop. The following graphs show all closed triangular loops (loops formed by three treatments) in efficacy and safety outcome network. Inconsistent loops are those that present IF with 95% CIs incompatible with zero. There are no inconsistent loops in all outcomes.

Supplemental Table 1. Definitions of the outcomes in included trials

Study	the Efficacy Outcome	the Safety Outcome
Hokusai-VTE	The primary efficacy outcome was **the incidence of adjudicated symptomatic recurrent venous thromboembolism,** which was defined as a composite of deep-vein thrombosis or nonfatal or fatal pulmonary embolism.	The pre-specified outcome measures for bleeding were **the composite of major and clinically relevant non-major bleeding** during the study treatment period**. Major bleeding** was defined as acute clinically overt bleeding accompanied by one or more of the following: a decrease in the blood hemoglobin level of 2 g/dL or more; transfusion of two or more units of packed red blood cells; critical site bleeding; bleeding into the operated joint requiring reoperation or intervention; intramuscular bleeding with compartment syndrome; or fatal bleeding**. Clinically relevant non-major bleeding** did not meet criteria for major bleeding and met the descriptions provided, including epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, hemoptysis, and hematoma**.**
AMPLIFY	The primary efficacy outcome was the incidence of the **adjudicated composite of recurrent symptomatic venous thromboembolism or death related to venous thromboembolism.** Recurrent venous thromboembolism included fatal or non- fatal pulmonary embolism and deep-vein thrombosis**.** Death was adjudicated as related to venous thromboembolism, related to cardiovascular disease, caused by bleeding, or due to other causes.	The primary safety outcome was **adjudicated major bleeding.** Bleeding was defined as major if it was overt and associated with a decrease in the hemoglobin level of 2 g per deciliter or more, required the transfusion of 2 or more units of blood, occurred into a critical site, or contributed to death.
AMPLIFY-EXT		**A composite of major bleeding and clinically relevant nonmajor bleeding. Major leeding** was defined as a decrease in the hemoglobin level of 2 g per deciliter or more, required the transfusion of 2 or more units of blood, occurred into a critical site, or contributed to death**. Clinically relevant nonmajor bleeding** was defined as overt bleeding that did not meet the criteria for major bleeding but that was associated with the need for medical intervention, unscheduled contact with a physician, interruption or discontinuation of the study drug, or discomfort or impairment of activities of daily living**.**
RE-MEDY	The primary efficacy outcome was **recurrent symptomatic and objectively verified venous thromboembolism or death associated with venous thromboembolism.** Clinically suspected recurrent deep-vein thrombosis had to be objectively verified using pre-specified imaging studies.	Safety outcomes included **major bleeding and clinically relevant nonmajor bleeding. Major bleeding** was defined as clinically overt and associated with a fall of the hemoglobin level of 20 g/L or required transfusion of at least 2 units of red cells or, involved a critical organ or was fatal**. Clinically relevant non-major bleeding**: At least one of the following criteria had to be fulfilled: 1) Spontaneous skin hematoma of at least 25 cm; 2) Spontaneous nose bleed of more than 5 minutes duration; 3) Macroscopic hematuria, either spontaneous or, if associated with an intervention; 4) Spontaneous rectal bleeding; 5) Gingival bleeding for more than 5 minutes; 6)Bleeding leading to hospitalization and/or requiring surgical treatment; 7) Bleeding leading to a transfusion of less than 2 units of whole blood or red cells; 8) Any other bleeding event considered clinically relevant by the investigator
RE-SONATE		
EINSTEIN-EXT/ EINSTEIN-DVT	The primary efficacy outcome was **symptomatic, recurrent venous thromboembolism**, defined as the composite of deep-vein thrombosisor nonfatal or fatal pulmonary embolism**. Recurrent pulmonary embolism** were defined as one or more of the following findings: a new intraluminal filling defect on spiral CT or pulmonary angiography, a cutoff of a vessel of more than 2.5 mm in diameter on pulmonary angiography, a new perfusion defect of at least 75% of a segment with corresponding normal ventilation, a new non–high-probability perfusion defect associated with deep venous thrombosis as documented by ultrasonography or venography, or a new pulmonary embolism confirmed at autopsy. **Recurrent deep venous thrombosis** was defined as one or more of the following findings: a new noncompressible venous segment or a substantial increase (4 mm or more) in the diameter of the thrombus during full compression in a previously abnormal segment on ultrasonography or a new intraluminal filling defect on venography**.**	**The composite of major or clinically relevant nonmajor bleeding. Major bleeding:** if it was clinically overt and was associated with a decrease in the hemoglobin level of ⩾2.0 g/dl; if bleeding led to the transfusion of ⩾2 units of red cells; or if bleeding was intracranial or retroperitoneal, occurred in another critical site, or contributed to death**. Clinically relevant nonmajor bleeding** was defined as overt bleeding that did not meet the criteria for major bleeding but was associated with medical intervention, unscheduled contact with a physician, interruption or discontinuation of a study drug, or discomfort or impairment of daily activities**.**
RE-COVER I/II	The primary efficacy outcome was **recurrent, symptomatic objectively confirmed venous thromboembolism (i.e., pulmonary embolism or deep-vein thrombosis) or venous thromboembolism related death**, assessed from randomization up to the end of treatment.	A composite of **major bleeding and clinically relevant nonmajor bleeding. Major bleeding** was defined according to International Society on Thrombosis and Haemostasis (ISTH) criteria**.** Definition of **clinically relevant non-major bleeding**: At least one of the following criteria had to be fulfilled: 1) Spontaneous skin hematoma of at least 25 cm2; 2) Spontaneous nose bleed of more than 5 minutes duration; 3) Macroscopic hematuria, either spontaneous or, if associated with an intervention, lasting more than 24 hours; 4) Spontaneous rectal bleeding (more than spotting on toilet paper); 5) Gingival bleeding for more than 5 minutes; 6) Bleeding leading to hospitalization and/or requiring surgical treatment; 7) Bleeding leading to a transfusion of less than 2 units of whole blood or red cells; 8) Any other bleeding event considered clinically relevant by the investigator**.**
EINSTEIN CHOICE/ EINSTEIN-PE	The primary efficacy outcome was **a composite of symptomatic, recurrent fatal or nonfatal venous thromboembolism and unexplained death for which pulmonary embolism could not be ruled out.** Recurrent venous thromboembolism included fatal and nonfatal pulmonary embolism and deep-vein thrombosis.	The principal safety outcome was **a composite of major or clinically relevant nonmajor bleeding. Major bleeding** was defined as overt bleeding that was associated with a decrease in the hemoglobin level of 2 g per deciliter or more, led to transfusion of 2 or more units of red cells, occurred in a critical site, or contributed to death**. Clinically relevant nonmajor bleeding** was defined as overt bleeding that did not meet the criteria for major bleeding but was associated with the need for medical intervention, unscheduled contact with a physician, interruption or discontinuation of the study drug, or discomfort or impairment of activities of daily living

Supplemental Table 2. Characteristics of included trials

Study	Year	Age	Male (%)	Sample size	Anticoagulant indication	Follow-up (months)	Excluded CrCl profile (mL/min)	Subgroup of CrCl (mL/min)	Intervention	Control	Efficacy outcomes	Safety outcomes
Hokusai-VTE	2013	56	57	8240	Acute symptomatic DVT and/or PE	12	<30	30-50 (n=541) >50 (n=7699)	Edoxaban 60mg once daily or 30mg once daily in patients with eGFR 30-50mL/min	Warfarin, INR 2.0-3.0	Composite of DVT or PE	Major or clinically relevant minor bleeding
AMPLIFY	2013	57	59	4783	Symptomatic DVT or PE	6	<25	25-50 (n=327) 50-80 (n=1061) >80 (n=3395)	Apixaban 10mg twice daily for the first 7 days, followed by 5 mg twice daily for 6 months	Warfarin, INR 2.0-3.0	Recurrent VTE or death related to VTE	Major bleeding
AMPLIFY-EXT	2013	57	58	2413	Symptomatic DVT or PE treated for 6 to 12 months with anticoagulant therapy	6	<25	25-50 (n=138) 50-80 (n=536) >80 (n=1739)	Apaixaban 2.5 or 5mg twice daily	Placebo	Recurrent VTE or death related to VTE	Major bleeding
RE-MEDY	2013	59	61	2824	Symptomatic DVT/PE already treated with anticoagulant or treated in RE-COVER I/II trials	6	<30	30-50 (n=104) 50-80 (n=617) >80 (n=2103)	Dabigatran 150 mg twice daily	Warfarin, INR 2.0-3.0	Recurrent VTE or death related to VTE	None
RE-SONATE	2013	56	55	1339	Symptomatic DVT/PE already treated with anticoagulant or treated in RE-COVER I/II trials	18	<30	30-50 (n=71) 50-80 (n=334) >80 (n=934)	Dabigatran 150 mg twice daily	Placebo	Recurrent VTE or death related to VTE	None
EINSTEIN-DVT	2010	56	56	3405	Acute symptomatic DVT	12	<30	30-50 (n=250) 50-80 (n=792) >80 (n=2363)	Rivaroxaban 15 mg twice daily for 3 weeks then 20 mg once daily	Warfarin, INR 2.0-3.0	DVT or non-fatal or fatal PE	Major or clinically relevant minor bleeding
EINSTEIN-EXT	2010	58	58	1088	Symptomatic DVT or PE who had been treated for 6 or 12 months with a vitamin K antagonist or rivaroxaban	12	<30	30-50 (n=86) 50-80 (n=256) >80 (n=746)	Rivaroxaban 20 mg once daily	Placebo	DVT or non-fatal or fatal PE	Major or clinically relevant minor bleeding
EINSTEIN-PE	2012	58	53	4806	Acute symptomatic PE	12	<30	30-50 (n=404) 50-80 (n=1230) >80 (n=3172)	Rivaroxaban 15 mg twice daily for 3 weeks then 20 mg once daily	Warfarin, INR 2.0-3.0	Recurrent VTE	Major or clinically relevant minor bleeding
RE-COVER I/II	2017	55	60	5035	Acute symptomatic proximal DVT or PE	6	<30	30-50 (n=237) 50-80 (n=1100) >80 (n=3698)	Dabigatran 150 mg twice daily	Warfarin, INR 2.0-3.0	Recurrent VTE or death related to VTE	Major or clinically relevant minor bleeding
EINSTEIN CHOICE	2017	58	55	3365	Symptomatic DVT or PE treated for 6 to 12 months with anticoagulant therapy	12	<30	30-50 (n=156) 50-80 (n=858) >80 (n=2351)	Rivaroxaban 10mg or 20mg once daily	Aspirin	Recurrent VTE	Major or clinically relevant minor bleeding

CKD = chronic kidney disease; CrCl = creatinine clearance; DVT = deep vein thrombosis; INR = international normalized ratio; PE = pulmonary embolism; VTE = venous thromboembolism.

Supplemental Table 3. Assessment of risk of bias in included trials

Component Study	Bias arising from the randomization process	Bias due to deviations from intended interventions	Bias due to missing outcome data	Bias in measurement of the outcome	Bias in selection of the reported result	Risk-of-bias judgment
Hokusai-VTE	Low	Low	Low	Low	Low	Low
AMPLIFY	Low	Low	Low	Low	Low	Low
AMPLIFY-EXT	Low	Low	Low	Low	Low	Low
RE-MEDY	Low	Low	Low	Low	Low	Low
RE-SONATE	Low	Low	Low	Low	Low	Low
EINSTEIN-DVT	Low	Low	High	Low	Low	Some concern
EINSTEIN-EXT	Low	Low	Low	Low	Low	Low
EINSTEIN-PE	Low	Low	High	Low	Low	Some concern
RE-COVER I/II	Low	Low	Low	Low	Low	Low
EINSTEIN CHOICE	Low	Low	Low	Low	Low	Low

Supplemental Table 4. Summary strength of evidence (SOE) ratings for directed comparisons

Quality assessment								No of patients		Effect	Quality
Populations	**Outcomes**	**No of studies**	**Risk of bias**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other considerations**	**Intervention**	**Control**	**OR (95% CI)**	
the treatment of acute VTE	VTE or VTE-related death	5	no serious risk of bias	no serious inconsistency	no serious indirectness	no serious imprecision	none	341/13117	362/13152	0.96 (0.82 to 1.11)	⊕⊕⊕⊕
								2.6%	2.8%		HIGH
	Bleeding events	5	no serious risk of bias	serious	no serious indirectness	no serious imprecision	none	1099/13075	1374/13107	0.76 (0.68 to 0.90)	⊕⊕⊕O
								8.4%	10.4%		MODERATE
the extended treatment of VTE	VTE or VTE-related death	4	no serious risk of bias	no serious inconsistency	no serious indirectness	serious	none	44/3581	125/2189	0.23 (0.16 to 0.29)	⊕⊕⊕O
								1.2%	5.7%		MODERATE
	Bleeding events	3	no serious risk of bias	serious	no serious indirectness	serious	none	159/4382	50/2744	1.86 (1.04 to 3.30)	⊕⊕O
								3.6%	1.8%		LOW

Abbreviations: CI = confidence intervals; OR = odds ratio; VTE = venous thromboembolism.

Population	Outcomes	Model assumption	*Dbar*	*Pd*	*DIC*	Accept Model
CrCl: 30-50 mL/min	the efficacy outcome	**Fixed consistency**	**76**	**15**	**91**	**Fixed consistency**
		Fixed inconsistency	78	16	94	
		Random consistency	75	17	92	
		Random inconsistency	78	17	95	
	the safety outcome	**Fixed consistency**	**83**	**14**	**97**	**Fixed consistency**
		Fixed inconsistency	84	15	99	
		Random consistency	83	15	98	
		Random inconsistency	83	16	99	
CrCl: 50-80 mL/min	the efficacy outcome	**Fixed consistency**	**113**	**18**	**131**	**Fixed consistency**
		Fixed inconsistency	118	18	136	
		Random consistency	110	22	132	
		Random inconsistency	112	22	134	
	the safety outcome	**Fixed consistency**	**112**	**17**	**129**	**Fixed consistency**
		Fixed inconsistency	113	17	130	
		Random consistency	112	19	131	
		Random inconsistency	113	20	133	
CrCl: >80 mL/min	the efficacy outcome	**Fixed consistency**	**117**	**16**	**133**	**Fixed consistency**
		Fixed inconsistency	118	16	134	
		Random consistency	115	18	133	
		Random inconsistency	117	19	136	
	the safety outcome	**Fixed consistency**	**108**	**16**	**124**	**Fixed consistency**
		Fixed inconsistency	109	16	125	
		Random consistency	109	16	125	
		Random inconsistency	111	16	127	

Supplemental Table 5. Evaluation of the model fit.

The table shows the mean posterior deviance (Dbar), the leverage (Pd, also termed the effective number of parameters) and the Deviance Information Criterion (DIC) of each model for outcome. The DIC means a measure of model fit that penalises model complexity – lower values of the DIC suggest a more parsimonious model.

Drugs	Efficacy			Safety		
	SUCRA	95%CrI	Rank	SUCRA	95%CrI	Rank
CrCl 30-50mL/min						
Dabigatran 150mg	0.88	0.33 to 1	1	0.51	0 to 1	3
Edoxaban 30mg	0.79	0.33 to 1	2	0.48	0 to 1	5
Apixaban 5mg	0.61	0.17 to 1	3	0.49	0 to 1	4
Rivaroxaban 20mg	0.47	0.17 to 0.83	4	0.38	0 to 0.83	6
Warfarin	0.43	0.17 to 0.67	5	0.13	0 to 0.5	7
Apixaban 2.5mg	0.29	0 to 1	6	0.67	0 to 1	2
Placebo	0.04	0 to 0.17	7	0.84	0 to 1	1
CrCl 50-80mL/min						
Rivaroxaban 20mg	0.85	0.5 to 1	1	0.294	0 to 0.63	8
Edoxaban 60mg	0.78	0.38 to 1	2	0.342	0.13 to 0.75	7
Warfarin	0.7	0.38 to 1	3	0.083	0 to 0.38	9
Dabigatran 150mg	0.53	0.13 to 1	4	0.446	0.13 to 0.75	6
Apixaban 5mg	0.51	0.13 to 1	5	0.67	0.13 to 0.88	2
Rivaroxaban 10mg	0.5	0.12 to 1	6	0.531	0 to 1	4
Apixaban 2.5mg	0.46	0.12 to 1	7	0.665	0 to 1	3
Aspirin	0.14	0 to 0.5	8	0.486	0 to 0.88	5
Placebo	0.05	0 to 0.25	9	0.983	0.87 to 1	1
CrCl >80mL/min						
Rivaroxaban 10mg	0.85	0.29 to 1	1	0.26	0 to 0.57	6
Rivaroxaban 20mg	0.64	0.29 to 1	2	0.11	0 to 0.29	7
Warfarin	0.61	0.29 to 1	3	0.1	0 to 0.29	8
Apixaban 5mg	0.56	0.14 to 1	4	0.75	0.71 to 1	3
Dabigatran 150mg	0.56	0.14 to 1	5	0.43	0.29 to 0.57	5
Apixaban 2.5mg	0.56	0.14 to 1	6	0.91	0.71 to 1	1
Aspirin	0.22	0 to 0.71	7	0.53	0.29 to 0.71	4
Placebo	0.01	0 to 0.14	8	0.9	0.71 to 1	2

Supplement Table 6. SUCRA and its 95% CrI for the primary efficacy and safety outcomes in VTE population with different CrCl.

Apixaban and Dabigatran were administrated twice daily, and others once daily. CrCl = creatinine clearance; CrI = credible intervals; SUCRA = surface under the cumulative ranking curve.

Supplement Table 7. Summary of confidence ratings for mixed and indirected comparisons in network meta-analysis.

Comparison	Number of studies	Within-study bias	Across-studies bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Mixed evidence of the efficacy outcome in patients with CrCl 30-50mL/min								
apixaban 2.5mg:apixaban 5mg	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:placebo	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:placebo	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:warfarin	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
dabigatran 150mg:placebo	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
dabigatran 150mg:warfarin	2	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
edoxaban 30mg:warfarin	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
placebo:rivaroxaban 20mg	1	No concerns	Suspected	Some concerns	Major concerns	No concerns	No concerns	Very low
rivaroxaban 20mg:warfarin	2	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
Indirect evidence of the efficacy outcome in patients with CrCl 30-50mL/min								
apixaban 2.5mg:dabigatran 150mg	0	No concerns	Undetected	Some concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:edoxaban 30mg	0	No concerns	Undetected	Some concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:warfarin	0	No concerns	Suspected	Some concerns	Major concerns	No concerns	No concerns	Very low
apixaban 5mg:dabigatran 150mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:edoxaban 30mg	0	No concerns	Undetected	Some concerns	Major concerns	No concerns	No concerns	Very low
apixaban 5mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
dabigatran 150mg:edoxaban 30mg	0	No concerns	Suspected	Some concerns	Major concerns	No concerns	No concerns	Very low
dabigatran 150mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
edoxaban 30mg:placebo	0	No concerns	Suspected	Some concerns	No concerns	Major concerns	No concerns	Very low
edoxaban 30mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
placebo:warfarin	0	No concerns	Suspected	Some concerns	Major concerns	No concerns	No concerns	Very low
Mixed evidence of the efficacy outcome in patients with CrCl 50-80mL/min								
apixaban 2.5mg:apixaban 5mg	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:placebo	1	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
apixaban 5mg:placebo	1	No concerns	Undetected	No concerns	No concerns	No concerns	No concerns	Moderate
apixaban 5mg:warfarin	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
aspirin:rivaroxaban 10mg	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
aspirin:rivaroxaban 20mg	1	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
dabigatran 150mg:placebo	1	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
dabigatran 150mg:warfarin	2	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
edoxaban 60mg:warfarin	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
placebo:rivaroxaban 20mg	1	No concerns	Undetected	No concerns	No concerns	No concerns	No concerns	Moderate
rivaroxaban 10mg:rivaroxaban 20mg	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
rivaroxaban 20mg:warfarin	2	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low

Comparison	Number of studies	Within-study bias	Across-studies bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Indirect evidence of the efficacy outcome in patients with CrCl 50-80mL/min								
apixaban 2.5mg:aspirin	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:dabigatran 150mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:edoxaban 60mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:rivaroxaban 10mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:warfarin	0	No concerns	Suspected	No concerns	Major concerns	No concerns	No concerns	Very low
apixaban 5mg:aspirin	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:dabigatran 150mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:edoxaban 60mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:rivaroxaban 10mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
aspirin:dabigatran 150mg	0	No concerns	Undetected	Some concerns	Major concerns	No concerns	No concerns	Very low
aspirin:edoxaban 60mg	0	No concerns	Suspected	Some concerns	Major concerns	No concerns	No concerns	Very low
aspirin:placebo	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
aspirin:warfarin	0	No concerns	Suspected	Some concerns	Major concerns	No concerns	No concerns	Very low
dabigatran 150mg:edoxaban 60mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
dabigatran 150mg:rivaroxaban 10mg	0	No concerns	Suspected	Some concerns	Major concerns	No concerns	No concerns	Very low
dabigatran 150mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
edoxaban 60mg:placebo	0	No concerns	Suspected	Some concerns	No concerns	No concerns	No concerns	Very low
edoxaban 60mg:rivaroxaban 10mg	0	No concerns	Suspected	Some concerns	Major concerns	No concerns	No concerns	Very low
edoxaban 60mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
placebo:rivaroxaban 10mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
placebo:warfarin	0	No concerns	Suspected	Some concerns	No concerns	No concerns	No concerns	Very low
rivaroxaban 10mg:warfarin	0	No concerns	Suspected	Some concerns	Major concerns	No concerns	No concerns	Very low
Mixed evidence of the efficacy outcome in patients with CrCl >80mL/min								
apixaban 2.5mg:apixaban 5mg	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:placebo	1	No concerns	Undetected	No concerns	No concerns	No concerns	No concerns	Moderate
apixaban 5mg:placebo	1	No concerns	Undetected	No concerns	No concerns	No concerns	No concerns	Moderate
apixaban 5mg:warfarin	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
aspirin:rivaroxaban 10mg	1	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
aspirin:rivaroxaban 20mg	1	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
dabigatran 150mg:placebo	1	No concerns	Undetected	Some concerns	No concerns	No concerns	No concerns	Low
dabigatran 150mg:warfarin	2	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
placebo:rivaroxaban 20mg	1	No concerns	Undetected	No concerns	No concerns	No concerns	No concerns	Moderate
rivaroxaban 10mg:rivaroxaban 20mg	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
rivaroxaban 20mg:warfarin	2	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low

Comparison	Number of studies	Within-study bias	Across-studies bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Indirect evidence of the efficacy outcome in patients with CrCl >80mL/min								
apixaban 2.5mg:aspirin	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:dabigatran 150mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:rivaroxaban 10mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:warfarin	0	No concerns	Suspected	Some concerns	Major concerns	No concerns	No concerns	Very low
apixaban 5mg:aspirin	0	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
apixaban 5mg:dabigatran 150mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:rivaroxaban 10mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
aspirin:dabigatran 150mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
aspirin:placebo	0	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
aspirin:warfarin	0	No concerns	Suspected	Some concerns	No concerns	Major concerns	No concerns	Very low
dabigatran 150mg:rivaroxaban 10mg	0	No concerns	Suspected	Some concerns	Major concerns	No concerns	No concerns	Very low
dabigatran 150mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
placebo:rivaroxaban 10mg	0	No concerns	Undetected	No concerns	No concerns	No concerns	No concerns	Moderate
placebo:warfarin	0	No concerns	Suspected	Some concerns	No concerns	No concerns	No concerns	Very low
rivaroxaban 10mg:warfarin	0	No concerns	Suspected	Some concerns	Major concerns	No concerns	No concerns	Very low
Mixed evidence of the safety outcome in patients with CrCl 30-50mL/min								
apixaban 2.5mg:apixaban 5mg	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:placebo	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:placebo	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:warfarin	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
dabigatran 150mg:warfarin	2	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
edoxaban 30mg:warfarin	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
placebo:rivaroxaban 20mg	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
rivaroxaban 20mg:warfarin	2	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
Indirect evidence of the safety outcome in patients with CrCl 30-50mL/min								
apixaban 2.5mg:dabigatran 150mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:edoxaban 30mg	0	No concerns	Suspected	Some concerns	Major concerns	No concerns	No concerns	Very low
apixaban 2.5mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:warfarin	0	No concerns	Undetected	Some concerns	Major concerns	No concerns	No concerns	Very low
apixaban 5mg:dabigatran 150mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:edoxaban 30mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
dabigatran 150mg:edoxaban 30mg	0	No concerns	Undetected	Some concerns	Major concerns	No concerns	No concerns	Very low
dabigatran 150mg:placebo	0	No concerns	Suspected	No concerns	Major concerns	No concerns	No concerns	Very low
dabigatran 150mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
edoxaban 30mg:placebo	0	No concerns	Suspected	Some concerns	Major concerns	No concerns	No concerns	Very low
edoxaban 30mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
placebo:warfarin	0	No concerns	Suspected	Some concerns	Major concerns	No concerns	No concerns	Very low

Comparison	Number of studies	Within-study bias	Across-studies bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Mixed evidence of the efficacy outcome in patients with CrCl 50-80mL/min								
apixaban 2.5mg:apixaban 5mg	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:placebo	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:placebo	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:warfarin	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
aspirin:rivaroxaban 10mg	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
aspirin:rivaroxaban 20mg	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
dabigatran 150mg:warfarin	2	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
edoxaban 60mg:warfarin	1	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
placebo:rivaroxaban 20mg	1	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
rivaroxaban 10mg:rivaroxaban 20mg	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
rivaroxaban 20mg:warfarin	2	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
Indirect evidence of the safety outcome in patients with CrCl 50-80mL/min								
apixaban 2.5mg:aspirin	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:dabigatran 150mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:edoxaban 60mg	0	No concerns	Suspected	No concerns	Major concerns	No concerns	No concerns	Very low
apixaban 2.5mg:rivaroxaban 10mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:warfarin	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:aspirin	0	No concerns	Undetected	Some concerns	Major concerns	No concerns	No concerns	Very low
apixaban 5mg:dabigatran 150mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:edoxaban 60mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:rivaroxaban 10mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
aspirin:dabigatran 150mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
aspirin:edoxaban 60mg	0	No concerns	Suspected	No concerns	Major concerns	No concerns	No concerns	Very low
aspirin:placebo	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
aspirin:warfarin	0	No concerns	Undetected	Some concerns	Major concerns	No concerns	No concerns	Very low
dabigatran 150mg:edoxaban 60mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
dabigatran 150mg:placebo	0	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
dabigatran 150mg:rivaroxaban 10mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
dabigatran 150mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
edoxaban 60mg:placebo	0	No concerns	Suspected	Some concerns	No concerns	Major concerns	No concerns	Very low
edoxaban 60mg:rivaroxaban 10mg	0	No concerns	Suspected	No concerns	Major concerns	No concerns	No concerns	Very low
edoxaban 60mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
placebo:rivaroxaban 10mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
placebo:warfarin	0	No concerns	Suspected	Some concerns	No concerns	Major concerns	No concerns	Very low
rivaroxaban 10mg:warfarin	0	No concerns	Undetected	Some concerns	Major concerns	No concerns	No concerns	Very low

Comparison	Number of studies	Within-study bias	Across-studies bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Mixed evidence of the safety outcome in patients with CrCl >80mL/min								
apixaban 2.5mg:apixaban 5mg	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 2.5mg:placebo	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:placebo	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:warfarin	1	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
aspirin:rivaroxaban 10mg	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
aspirin:rivaroxaban 20mg	1	No concerns	Undetected	Some concerns	No concerns	Major concerns	No concerns	Very low
dabigatran 150mg:warfarin	2	No concerns	Undetected	No concerns	No concerns	No concerns	No concerns	Moderate
placebo:rivaroxaban 20mg	1	No concerns	Suspected	Some concerns	No concerns	No concerns	No concerns	Very low
rivaroxaban 10mg:rivaroxaban 20mg	1	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
rivaroxaban 20mg:warfarin	2	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
Indirect evidence of the safety outcome in patients with CrCl >80mL/min								
apixaban 2.5mg:aspirin	0	No concerns	Undetected	Some concerns	No concerns	Major concerns	No concerns	Very low
apixaban 2.5mg:dabigatran 150mg	0	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
apixaban 2.5mg:rivaroxaban 10mg	0	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
apixaban 2.5mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
apixaban 2.5mg:warfarin	0	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
apixaban 5mg:aspirin	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
apixaban 5mg:dabigatran 150mg	0	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Moderate
apixaban 5mg:rivaroxaban 10mg	0	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
apixaban 5mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
aspirin:dabigatran 150mg	0	No concerns	Undetected	Some concerns	Major concerns	No concerns	No concerns	Very low
aspirin:placebo	0	No concerns	Undetected	Some concerns	No concerns	Major concerns	No concerns	Very low
aspirin:warfarin	0	No concerns	Suspected	No concerns	No concerns	Major concerns	No concerns	Very low
dabigatran 150mg:placebo	0	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
dabigatran 150mg:rivaroxaban 10mg	0	No concerns	Undetected	No concerns	Major concerns	No concerns	No concerns	Low
dabigatran 150mg:rivaroxaban 20mg	0	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
placebo:rivaroxaban 10mg	0	No concerns	Undetected	No concerns	No concerns	Major concerns	No concerns	Low
placebo:warfarin	0	No concerns	Suspected	Some concerns	No concerns	No concerns	No concerns	Very low
rivaroxaban 10mg:warfarin	0	No concerns	Suspected	Some concerns	Major concerns	No concerns	No concerns	Very low

Supplemental Item 1. Search Strategy

1) Ovid MEDLINE (1946 to 2019 Week 26) and Ovid Embase (1966-July 1, 2019)

1. exp anticoagulant agent/ or exp blood clotting inhibitor/ or exp coumarin anticoagulant/ or exp 4 hydroxycoumarin derivative/ or exp warfarin/ or exp Acenocoumarol/ or exp Dicumarol/ or exp Phenprocoumon/ or exp Phenindione/ or exp thrombin inhibitor/ or exp dabigatran/ or exp blood clotting factor 10a inhibitor/ or exp apixaban/ or exp betrixaban/ or exp edoxaban/ or exp rivaroxaban/
2. exp Renal Dialysis/ or exp Renal Replacement Therapy/ or exp Kidney Failure, Chronic/ or exp Renal Insufficiency/ or Renal Insufficiency, Chronic/ or exp Kidney Diseases/ or exp Kidney Transplantation/ or exp glomerular filtration rate/ or exp kidney function test/ or exp creatinine/ or creatinine clearance.tw.
3. exp Clinical trial/ or exp Controlled clinical trial/ or exp Randomized Controlled Trials/ or exp Random Allocation/ or exp Cohort Studies/ or exp Longitudinal Studies/ or exp Follow-Up Studies/ or exp Prospective Studies/ or exp Retrospective Studies/
4. 1 and 2 and 3
5. limit 8 to humans

2) CENTRAL (before July 2019)

#1. MeSH descriptor: [anticoagulants] explode all trees
#2. anticoagulants:ti,ab
#3. “vitamin k dependent anticoagulant*” or “vitamin k antagonist*”:ti,ab
#4. Factor Xa inhibitor$
#5. warfarin or coumadin* or aldocumar or tedicumar
#6. rivaroxaban or apixaban or edoxaban or dabigatran or betrixaban or pradaxa or eliques or eliquis or Xarelto or anticoagulation or anticoagulant$
#7. #1 OR #2 OR #3 OR #4 OR #5 OR #6
#8. MeSH descriptor: [Kidney Diseases] explode all trees
#9. “Kidney Disease$”:ti,ab
#10. MeSH descriptor: [renal insufficiency, chronic] explode all trees
#11. 'renal insufficiency, chronic':ti,ab
#12. chronic kidney disease* or chronic renal disease* or chronic kidney insufficiency or chronic renal insufficiency or chronic kidney injury or chronic renal injury or chronic renal failure or chronic kidney failure
#13. MeSH descriptor: [dialysis] explode all trees
#14. ‘dialysis’:ti,ab
#15. ("end-stage renal" or "end-stage kidney" or "end stage renal" or "end stage kidney") next (disease or failure)
#16. MeSH descriptor: [Uremia] explode all trees
#17. ‘ur?emi*’:ti,ab

#18. MeSH descriptor: [renal replacement therapy] explode all trees

#19. 'renal replacement therapy':ti,ab

#20. h?emodialysis or h?emofiltration or h?emodiafiltration

#21. MeSH descriptor: [Peritoneal Dialysis] explode all trees

#22. 'Peritoneal Dialys*':ti,ab

#23. #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22

#24. #7 and #23

Reporting checklist for systematic review and meta-analysis.

Based on the PRISMA guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMAreporting guidelines, and cite them as:

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

		Reporting Item	Page Number
Title			
	#1	Identify the report as a systematic review, meta-analysis, or both.	1
Abstract			
Structured summary	#2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number	2
Introduction			
Rationale	#3	Describe the rationale for the review in the context of what is already known.	4
Objectives	#4	Provide an explicit statement of questions being	4

		addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	
Methods			
Protocol and registration	#5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address) and, if available, provide registration information including the registration number.	4
Eligibility criteria	#6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rational	5
Information sources	#7	Describe all information sources in the search (e.g., databases with dates of coverage, contact with study authors to identify additional studies) and date last searched.	4,5
Search	#8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4,5 and online supplement item 1
Study selection	#9	State the process for selecting studies (i.e., for screening, for determining eligibility, for inclusion in the systematic review, and, if applicable, for inclusion in the meta-analysis).	5
Data collection process	#10	Describe the method of data extraction from reports (e.g., piloted forms, independently by two reviewers) and any processes for obtaining and confirming data from investigators.	5
Data items	#11	List and define all variables for which data were sought (e.g., PICOS, funding sources), and any assumptions and simplifications made.	5,6
Risk of bias in individual studies	#12	Describe methods used for assessing risk of bias in individual studies (including specification of whether this was done at the study or outcome level, or both), and how this information is to be used in any data synthesis.	5
Summary measures	#13	State the principal summary measures (e.g., risk ratio, difference in means).	6,7

Planned methods of analyis	#14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.	6,7
Risk of bias across studies	#15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	#16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
Results			
Study selection	#17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6
Study characteristics	#18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citation.	6, online supplemental table 2
Risk of bias within studies	#19	Present data on risk of bias of each study and, if available, any outcome-level assessment (see Item 12).	7, online supplemental table 3
Results of individual studies	#20	For all outcomes considered (benefits and harms), present, for each study: (a) simple summary data for each intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot.	7,8
Synthesis of results	#21	Present the main results of the review. If meta-analyses are done, include for each, confidence intervals and measures of consistency.	7,8
Risk of bias across studies	#22	Present results of any assessment of risk of bias across studies (see Item 15).	7, online supplemental table 3
Additional analysis	#23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	8
Discussion			

Summary of Evidence	#24	Summarize the main findings, including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., health care providers, users, and policy makers	9
Limitations	#25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of identified research, reporting bias).	9
Conclusions	#26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	12
Funding			
Funding	#27	Describe sources of funding or other support (e.g., supply of data) for the systematic review; role of funders for the systematic review.	12

Notes:

- 8: 4,5 and online supplement item 1
- 18: 6, online supplemental table 2
- 19: 7, online supplemental table 3
- 22: 7, online supplemental table 3 The PRISMA checklist is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist was completed on 02. January 2021 using https://www.goodreports.org/, a tool made by the EQUATOR Network in collaboration with Penelope.ai